Compare CNXC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | SRPT |
|---|---|---|
| Founded | 1991 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2020 | 2000 |
| Metric | CNXC | SRPT |
|---|---|---|
| Price | $26.46 | $20.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 28 |
| Target Price | ★ $54.80 | $25.40 |
| AVG Volume (30 Days) | 1.6M | ★ 3.2M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,825,771,000.00 | $2,198,237,000.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.15 | ★ 15.58 |
| 52 Week Low | $24.27 | $10.42 |
| 52 Week High | $62.14 | $67.47 |
| Indicator | CNXC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 56.41 |
| Support Level | N/A | $16.38 |
| Resistance Level | $34.64 | $23.01 |
| Average True Range (ATR) | 2.15 | 1.20 |
| MACD | -0.47 | 0.62 |
| Stochastic Oscillator | 23.56 | 49.54 |
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.